Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Business Model:
Revenue: $709.5M
Employees: 1,001-5,000
Oaktree Capital Management was acquired by
Brookfield Asset Management.
The acquisition happend on 2019-03-13.
Details of the transaction were not public
Address: 333 South Grand Avenue
City: Los Angeles
State: CA
Zip: 90071
Country: US
Oaktree’s mission is to provide highly professional management with a primary emphasis on risk control in a limited number of sophisticated investment specialties. Oaktree specializes in less efficient markets and alternative investments, and has extensive experience, an enviable track record, broad product range and substantial assets under management. They are dedicated to the achievement of consistent and superior performance without high risk. Their ultimate objective is investment success, the fruits of which are shared by Oaktree’s clients and personnel.
Contact Phone:
+12138306300
Contact Email:
Listed Exchange:
NYSE
IPO Date:
4/12/2012
IPO Valuation:
$1B
Ticker Symbol:
OAK
IPO Price:
$43/share
Amount Raised:
$380M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2016 | ezbob | Series C | 28.8M |
5/2021 | Marinus Pharmaceuticals | Post-IPO Debt | 45M |
2/2022 | b atomic | Seed | 1M |
6/2019 | SHINE Medical Technologies | Debt | 50M |
12/2019 | Marinus Pharmaceuticals | Equity | 30M |
10/2021 | Mission Lane | Debt Financing | 150M |
1/2022 | ABC Technologies | Post-IPO Equity | 269.5M |
3/2022 | Impel NeuroPharma | Post-IPO Debt | 50M |
4/2020 | Airbnb | Debt Financing | 1B |
3/2013 | Charter Communications | Post-IPO Equity | - |
2/2022 | Draslovka | Private Equity Round | 0 |
12/2021 | Montana Renewables | Debt Financing | 300M |
6/2019 | cure.fit | Series D | 120M |
11/2020 | REEF | Private Equity Round | 700M |
9/2021 | Priority Power Management | Private Equity Round | 250M |
4/2022 | BioXcel Therapeutics | Post-IPO Debt | 135M |
7/2020 | M3M India Limited | Debt Financing | 76M |
12/2021 | SiO2 Materials Science | Debt | 205M |
12/2020 | BKV Corporation | Venture Round | 100M |
12/2020 | brumbrum | Debt Financing | 65M |
6/2021 | Primary Wave | Private Equity Round | - |
9/2016 | ICICI Prudential Life Insurance | Private Equity Round | 0 |
3/2021 | SumUp | Debt Financing | 0 |
8/2020 | Fortress Biotech | Post-IPO Debt | 60M |
7/2016 | Array Technologies | Seed Round | - |
10/2011 | Panrico SA | Debt Financing | - |
10/2021 | Thrasio | Series D | 0 |
3/2021 | NN | Post-IPO Equity | 265M |
11/2016 | Sterling Lumber Company | Venture Round | - |
4/2014 | Enplug | Seed Round | 0 |
2/2018 | Kudu Investment Management | Funding Round | 0 |
3/2021 | RumbleON | Post-IPO Equity | 280M |
3/2016 | ProService Finteco | Private Equity Round | - |
7/2018 | cure.fit | Series C | 120M |
1/2022 | Unblocked | Seed Round | 0 |
10/2018 | Montrose | Private Equity Round | - |
9/2020 | Zzoomm Full Fibre Broadband | Series B | 128.7M |
6/2004 | Infraworks | Series B | 7.5M |
4/2021 | Thrasio | Series C | 0 |
4/2020 | SunOpta | Post-IPO Equity | 0 |
2/2021 | Thrasio | Series C | 750M |
9/2020 | Universal Plant Services | Secondary Market | - |
10/2016 | SunOpta | Post-IPO Equity | 85M |
4/2015 | ezbob | Debt Financing | 45.2M |
10/2022 | scPharmaceuticals | Post-IPO Debt | 100M |
1/2014 | Ten K Solar | Venture Round | 0 |
6/2019 | Costa Edutainment | Secondary Market | 45.5M |
8/2021 | Environmental 360 Solutions E360S | Venture Round | - |
7/2019 | Singular | Venture Round | - |
10/2018 | Assembled Brands | Funding Round | 100M |
12/2021 | Cvent | Post-IPO Equity | 0 |
9/2019 | Mission Lane | Debt Financing | 300M |
11/2021 | Elevate Brands | Venture Round | 0 |
4/2022 | BioXcel Therapeutics | Post-IPO Equity | 5M |
10/2018 | Blue Sky Private Equity | Post-IPO Debt | 35.9M |
11/2012 | Pulse Electronics | Post-IPO Equity | 102.7M |
2/2021 | Win Brands Group | Equity | 50M |
12/2021 | HealthCare.com | Series C | 0 |
7/2017 | DDH1 | Venture Round | - |
1/2021 | Thrasio | Debt Financing | 0 |
12/2020 | System One | Private Equity Round | - |
3/2016 | FortiFi | Series A | 75M |
3/2018 | Proserv | Private Equity Round | 50M |
6/2016 | Tribes | Venture Round | - |
4/2022 | BioXcel Therapeutics | Post-IPO Debt | 0 |
4/2022 | BioXcel Therapeutics | Post-IPO Equity | 0 |
3/2022 | Marinus Pharmaceuticals | Post-IPO Debt | 0 |
3/2022 | Impel NeuroPharma | Post-IPO Debt | 0 |
2/2022 | b atomic | Seed Round | 0 |
2/2022 | Draslovka | Private Equity Round | 0 |
1/2022 | Unblocked | Seed Round | 0 |
1/2022 | ABC Technologies | Post-IPO Equity | 0 |
12/2021 | SiO2 Materials Science | Debt Financing | 0 |
12/2021 | HealthCare.com | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|